Doxycycline

As an upgraded variety of tetracycline antibiotics, doxycycline reversibly binds to the 30S subunit of bacterial ribosomes and blocks the binding of aminoacyl-tRNA to ribosomes, thereby inhibiting bacterial protein synthesis. Its antibacterial spectrum covers Gram-positive bacteria, Gram-negative bacteria and atypical pathogens, and it is a first-line drug for the clinical treatment of rickettsiosis, mycoplasma pneumonia, chlamydia infection and brucellosis. It can also be used for adjuvant treatment of moderate to severe acne, and the applicable population includes adults and children over 8 years old. With high liposolubility, strong tissue penetration and oral bioavailability close to 90%, it has a lower incidence of adverse reactions than traditional tetracyclines, and has long occupied an irreplaceable clinical position in the field of anti-infection.

The global doxycycline market size has maintained steady growth in recent years. In 2023, the overall market size was approximately USD 1.28 billion, with a compound annual growth rate maintained at around 4.2%. As a mature variety that has been on the market for many years, its market is dominated by generic drugs. China is the world's largest producer and exporter of doxycycline API, with production capacity accounting for more than 75% of the global total capacity. After the implementation of domestic centralized procurement, the terminal price of preparations has dropped significantly, further driving the increase in demand for upstream APIs, and the capacity utilization rate of leading manufacturers has remained above 90% for a long time.

The original developer of doxycycline is Pfizer, with the original brand name Vibramycin. The core compound patent expired globally in 1972. At present, the main dosage forms of the original drug on the market include tablets (50mg, 100mg), injection (100mg), and oral suspension (25mg/5ml). Among them, the 100mg tablet has been included in the FDA Reference Listed Drug Catalog and China's *Catalog of Reference Preparations for Chemical Drugs*. According to the domestic API registration platform, more than 30 enterprises have obtained A-status registration numbers for doxycycline APIs, and the number of domestic preparation approvals exceeds 160, covering all mainstream dosage forms such as oral and injection. (Data as of October 2024, please refer to the official website of CDE for the latest information)

CATO can provide a full set of doxycycline impurity reference standards, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All reference standards meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can fully meet the reference substance needs of pharmaceutical enterprises in all links such as API R&D, quality research, and consistency evaluation.